

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number

09/910059

Filing Date

First-Named Inventor

Clive Graham COPI FSY

Group Art Unit

Examiner Name

ATTACH 12 to # 11

Sheet

1

of

3

Attorney Docket Number

1991-200

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number	Kind Code (if known)			
LA	AA	EP	633,029		Cancer Research Campaign Technology Ltd.	10-11-1995	
	AB	WO	95/15341		Cancer Research Campaign Technology Ltd.	06-08-1995	
	AC	WO	96/11013		Immunomedics	04-18-1996	
↓	AD	WO	92/01059		Celltech Ltd.	01-23-1992	
LA	AE	WO	94/25585/		Genpharm International Inc.	11-10-1994	
Examiner Signature	<i>LA 2</i>				Date Considered	<i>4/24/03</i>	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document. In the U.S. this is the U.S. Patent and Trademark Office.

⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>			
				Application Number		09/90059	
				Filing Date			
				First Named Inventor		Clive Graham Copley	
				Group Art Unit			
				Examiner Name			
Sheet	2	of	3	Attorney Docket Number	1991-209		
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ⁶		
LN	AF	Abraham, "Screening and kinetic analysis of recombinant anti-CEA antibody fragments," <i>Journal of Immunological Methods</i> , 183, 1995, pp. 119-125, Elsevier Science B.V.					
	AG	Accolla, "Monoclonal antibodies specific for carcinoembryonic antigen and produced by two hybrid cell lines," <i>Proc. Natl. Acad. Sci.</i> , 77, 1980, pp. 563-566					
	AH	Banjo, "Intermolecular heterogeneity of the Carcinoembryonic Antigen," <i>Cancer Research</i> , 34, August 1974, pp. 2114-2121					
	AI	Chandrasekaran, "Isolation and Structures of the Oligosaccharide Units of Carcinoembryonic Antigen," <i>The Journal of Biological Chemistry</i> , 258, 1983, pp. 7213-7222, U.S.A.					
	AJ	Chournoyer, "Transcription of Genes of the Carcinoembryonic Antigen Family in Malignant and Nonmalignant Human Tissues," <i>Cancer Research</i> , 48, 1988, pp. 3153-3157					
	AK	Durbin, "An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3," <i>Proc. Natl. Acad. Sci.</i> , 91, 1994, pp. 4313-4317					
	AL	Haggarty, "Epitopes of Carcinoembryonic Antigen Defined by Monoclonal Antibodies Prepared from Mice Immunized with Purified Carcinoembryonic Antigen or HCT-8R Cells," <i>Cancer Research</i> , 46, 1986, pp. 300-309					
	AM	Hammarstrom, "Antigenic Sites in Carcinoembryonic Antigen," <i>Cancer Research</i> , 49, 1989, pp. 4852-4858					
	AN	Hansen, "Characterization of Second-Generation Monoclonal Antibodies Against Carcinoembryonic Antigen," <i>Cancer</i> , 71, June 1993, pp. 3478-3485					
↓	AO	Hedin, "Specificities and binding properties of eight monoclonal antibodies against carcinoembryonic antigen," <i>Molecular Immunology</i> , 19, 1982, pp. 1641-1648, Pergamon Press Ltd., U.K.					
LN	AP	Hefta, "Expression of Carcinoembryonic Antigen and Its Predicted Immunoglobulin-like Domains in HeLa Cells for Epitope Analysis," <i>Cancer Research</i> , 52, October 1992, 5647-5655					
Examiner Signature			Date Considered	4/24/03			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>			
				Application Number		09/910059	
				Filing Date			
				First Named Inventor		Clive Graham Copley, et al.	
				Group Art Unit			
				Examiner Name			
Sheet	3	of	3	Attorney Docket Number	1991-209		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ⁶
LN	AQ	Konstadoulakis, "The Presence of Anti-Carcinoembryonic Antigen (CEA) Antibodies in the Sera of Patients with Gastrointestinal Malignancies," <i>Journal of Clinical Immunology</i> , 14, 1994, pp. 310-313			
	AR	Kuroki, "Purification and Characterization of Carcinoembryonic Antigen-related Antigens in Normal Adult Feces," <i>Cancer Research</i> , 41, February 1981, 713-718			
	AS	Kupchik, Monoclonal Antibodies to Carcinoembryonic Antigen Produced by Somatic Cell Fusion," <i>Cancer Research</i> , 41, September 1981, pp. 3306-3310			
	AT	Oikawa, "Primary Structure of Human Carcinoembryonic Antigen (CEA) Deduced from cDNA Sequence," <i>Biochemicals and Biophysical Research Communications</i> , 142, 1987, pp. 511-518			
	AU	Rogers, "Somatic-Cell Hybrids Producing Antibodies Against CEA," <i>Br. J. Cancer</i> , 43, 1981, pp. 1-4			
	AV	Thomas, "A Peptide Sequence on Carcinoembryonic Antigen Binds to a 80kD Protein on Kupffer Cells," <i>Biochemicals and Biophysical Research Communications</i> , 188, 1992, pp. 671-677			
	AW	D. Blakely et al., "Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.", <i>British Journal of Cancer</i> , Nov. 1995, pages 1083-1088, Vol. 72, No. 5, Basingstoke, GB			
	AX	M. Michael et al., "In vitro and in vivo characterization of a recombinant carboxypeptidase G2:anti-CEA scFv fusion protein," <i>Immunotechnology</i> , 1996, pages 47-57, vol. 2, no. 1, Amsterdam, NL.			
✓	AY	S. Leung et al., "Bacterial expression of a peptide fusion protein facilitates 32P labeling of a humanized, anti-carcinoembryonic antigen (hMN-14) antibody fragment," <i>Cancer Research</i> , Dec. 1, 1995, pages 5968S-5972S, vol. 55, no. 23, suppl., Baltimore, MD, USA			
AK	AZ	K. Bosslet et al., "Tumor-selective prodrug activation by fusion protein-mediated catalysis," <i>Cancer Research</i> , April 1, 1994, pages 2151-2159, vol. 54, no. 7, Baltimore, MD, USA			
Examiner Signature			Date Considered	4/24/03	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.